PRRT2 and cancer: Some kinases, such as EGFR (Ayati et al., 2020; Sabbah et al., 2020), VEGFR (Shibuya, 2011; Modi and Kulkarni, 2019; Wang et al., 2020), RAF kinases (Holderfield et al., 2014; Karoulia et al., 2017), PKC (Rui et al., 2017; Linciano et al., 2022), and Aurora kinases (Bavetsias and Linardopoulos, 2015; Yan et al., 2016), just to cite a few, are amplified in various cancer types and their dysregulation is associated with poor prognosis in cancers.